申请人:BANYU PHARMACEUTICAL CO., LTD.
公开号:EP1764362A1
公开(公告)日:2007-03-21
The present invention relates to a compound represented by the formula (I):
or a pharmaceutically acceptable salt thereof, whrein:
R1 is a linear or branched alkoxy group, a cycloalkoxy group, a linear or branched lower alkyl group, etc.; R2 is halogen atom, a lower alkyl group, etc.; Q1 is carbon atom or nitrogen atom; Q2 is carbon atom which may be substituted with oxo group; the formula (III) :
is a single bond or a double bond; A is a group selected from the group consisting of the substituent group α; and R5 is hydrogen atom, a lower alkyl group, cyano group, an alkoxy group or a trialkylsilyl group; having an mGluR1 inhibiting action and being useful as treatment and/or prevention of convulsion, acute pain, cerebral disturbance such as cerebral infarction or transient cerebral ischemia onset, anxiety, chemical dependency or Parkinson's disease.
本发明涉及一种由式 (I) 表示的化合物:
或其药学上可接受的盐,其中
R1 是直链或支链烷氧基、环烷氧基、直链或支链低级烷基等;R2 是卤素原子、低级烷基等;Q1 是碳原子或氮原子;Q2 是可被氧代基团取代的碳原子;式 (III) :
R5为氢原子、低级烷基、氰基、烷氧基或三烷基硅烷基;具有抑制 mGluR1 的作用,可用于治疗和/或预防抽搐、急性疼痛、脑梗塞或短暂性脑缺血发作等脑部障碍、焦虑、化学依赖或帕金森病。